Join Growin Stock Community!

逸達6576.TW Overview

TW StockBiotech. & Medical
(No presentation for 6576)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

逸達（6576）Overall Performance

逸達（6576）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

逸達（6576） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

逸達（6576）Key Information

逸達（6576）Profile

Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.

逸達（6576）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.30%
Net Margin
-235.89%
Revenue Growth (YoY)
49.93%
Profit Growth (YoY)
147.06%
3-Year Revenue Growth
105.43%
3-Year Profit Growth
444.48%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
73.30%
Net Margin
-235.89%
Revenue Growth (YoY)
49.93%
Profit Growth (YoY)
147.06%
3-Year Revenue Growth
105.43%
3-Year Profit Growth
444.48%

  • When is 6576's latest earnings report released?

    The most recent financial report for 逸達 (6576) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6576's short-term business performance and financial health. For the latest updates on 6576's earnings releases, visit this page regularly.

  • What is the operating profit of 6576?

    According to the latest financial report, 逸達 (6576) reported an Operating Profit of -116M with an Operating Margin of -73.91% this period, representing a growth of 60.37% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6576's revenue growth?

    In the latest financial report, 逸達 (6576) announced revenue of 156.95M, with a Year-Over-Year growth rate of 95.94%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6576 have?

    At the end of the period, 逸達 (6576) held Total Cash and Cash Equivalents of 854.57M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6576 go with three margins increasing?

    In the latest report, 逸達 (6576) did not achieve the “three margins increasing” benchmark, with a gross margin of 96.88%%, operating margin of -73.91%%, and net margin of -72.82%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6576's profit trajectory and future growth potential.

  • Is 6576's EPS continuing to grow?

    According to the past four quarterly reports, 逸達 (6576)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.74. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6576?

    逸達 (6576)'s Free Cash Flow (FCF) for the period is -200.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 119.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

default symbol

6576

逸達

82.50D

-1.21%

(-0.01)